Literature DB >> 412591

Systemic and regional treatment of primary carcinoma of the liver.

Y T Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 412591     DOI： 10.1016/s0305-7372(77)80024-8

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  7 in total

1.  Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Kyle D Holen; Donald W Northfelt; Henry C Pitot; Joel Picus; Patrick J Flynn; Charles Erlichman
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

Review 2.  Hepatic arterial chemotherapy for primary and metastatic liver cancers.

Authors:  W Ensminger
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Clinical decision analysis using microcomputers. A case of coexistent hepatocellular carcinoma and abdominal aortic aneurysm.

Authors:  J B Wong; A J Moskowitz; S G Pauker
Journal:  West J Med       Date:  1986-12

4.  Hepatoma.

Authors: 
Journal:  West J Med       Date:  1980-06

5.  High-dose mitomycin C: activity in hepatocellular carcinoma.

Authors:  A Cheirsilpa; S Leelasethakul; V Auethaveekiat; S Maoleekulpriroj; N Kangsumrit; P Thanakaravit; P Phanthumjida
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Right trisegmentectomy for hepatic neoplasms.

Authors:  T E Starzl; L J Koep; R Weil; J R Lilly; C W Putnam; J A Aldrete
Journal:  Surg Gynecol Obstet       Date:  1980-02

7.  A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.

Authors:  Tanios Bekaii-Saab; Joseph Markowitz; Nichole Prescott; Wolfgang Sadee; Nyla Heerema; Lai Wei; Zunyan Dai; Audrey Papp; Angela Campbell; Kristy Culler; Catherine Balint; Bert O'Neil; Ruey-Min Lee; Mark Zalupski; Janet Dancey; Helen Chen; Michael Grever; Charis Eng; Miguel Villalona-Calero
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.